Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.77 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438953 | 1.00 | EPHX2 (0.77) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL1497408 | 1.00 | EPHX2 (0.77) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL75195 | 0.84 | EPHX2 (0.74) | EPHX2EPHX1FAAHGAA | |
| SCHEMBL13834502 | 0.83 | EPHX2 (0.54) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL1694443 | 0.82 | EPHX2 (0.70) | EPHX2EPHX1FAAH | |
| SCHEMBL30500314 | 0.82 | EPHX2 (0.70) | EPHX2EPHX1FAAH | |
| SCHEMBL13834948 | 0.81 | EPHX2 (0.51) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL13834295 | 0.79 | EPHX2 (0.50) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL13834813 | 0.79 | EPHX2 (0.50) | EPHX2EPHX1FAAHGAAMAPK1 | |
| SCHEMBL25347526 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966200-B1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC (JP) | 2014-10-29 | — | — | EP | disclosed |
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270376-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK1, IRAK3 | EPHX2 1811/4885EPHX1 1534/4885FAAH 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.